Author
Listed:
- Veronika Ecker
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
- Martina Stumpf
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
- Lisa Brandmeier
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
- Tanja Neumayer
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
- Lisa Pfeuffer
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
- Thomas Engleitner
(TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich
Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University of Munich)
- Ingo Ringshausen
(Wellcome/MRC Cambridge Stem Cell Institute and Department of Haematology, Jeffrey Cheah Biomedical Centre, University of Cambridge)
- Nina Nelson
(Institute of Biochemistry and Signal Transduction, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf)
- Manfred Jücker
(Institute of Biochemistry and Signal Transduction, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf)
- Stefan Wanninger
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich)
- Thorsten Zenz
(University Hospital and University of Zurich)
- Clemens Wendtner
(Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians University (LMU))
- Katrin Manske
(Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München)
- Katja Steiger
(Institute of Pathology, Technische Universität München
German Cancer Consortium (DKTK))
- Roland Rad
(TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich
Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University of Munich
German Cancer Consortium (DKTK))
- Markus Müschen
(Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine)
- Jürgen Ruland
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich
German Cancer Consortium (DKTK)
German Center for Infection Research (DZIF), Partner Site Munich)
- Maike Buchner
(Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich
TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich)
Abstract
Current therapeutic approaches for chronic lymphocytic leukemia (CLL) focus on the suppression of oncogenic kinase signaling. Here, we test the hypothesis that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT (PI3K/AKT)-signaling pathway may be leveraged to trigger CLL cell death. Though counterintuitive, our data show that genetic hyperactivation of PI3K/AKT-signaling or blocking the activity of the inhibitory phosphatase SH2-containing-inositol-5′-phosphatase-1 (SHIP1) induces acute cell death in CLL cells. Our mechanistic studies reveal that increased AKT activity upon inhibition of SHIP1 leads to increased mitochondrial respiration and causes excessive accumulation of reactive oxygen species (ROS), resulting in cell death in CLL with immunogenic features. Our results demonstrate that CLL cells critically depend on mechanisms to fine-tune PI3K/AKT activity, allowing sustained proliferation and survival but avoid ROS-induced cell death and suggest transient SHIP1-inhibition as an unexpectedly promising concept for CLL therapy.
Suggested Citation
Veronika Ecker & Martina Stumpf & Lisa Brandmeier & Tanja Neumayer & Lisa Pfeuffer & Thomas Engleitner & Ingo Ringshausen & Nina Nelson & Manfred Jücker & Stefan Wanninger & Thorsten Zenz & Clemens We, 2021.
"Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia,"
Nature Communications, Nature, vol. 12(1), pages 1-17, December.
Handle:
RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23752-2
DOI: 10.1038/s41467-021-23752-2
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23752-2. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.